Earnings call briefSecond-quarter 2026
Merck says it expects U.S. Keytruda growth to moderate as it nears peak penetration
Merck said it expects the approximately $250 million benefit from wholesaler purchase timing in the third quarter of 2025 not to repeat this year.
GetSignal Merck MRK
On its second-quarter call, Merck said it expects total U.S. Keytruda year-over-year growth to moderate as it increasingly reaches peak penetration across several key indications.
Merck also said it expects third-quarter OHTUVAYRE sales to be affected by the unwind of second-quarter specialty pharmacy purchases. It said it expects these actions to lead to accelerated OHTUVAYRE growth in 2027.
Quotes from the call
“...we anticipate that total U.S. KEYTRUDA year-over-year growth will moderate as we increasingly reach peak penetration across several key indications.”
Key facts from the call
- Expected U.S. Keytruda year-over-year growth
- To moderate as peak penetration is increasingly reached
- Expected non-repeat of third-quarter 2025 wholesaler timing benefit
- Approximately $250 million
- Expected third-quarter OHTUVAYRE sales
- Affected by unwind of second-quarter specialty pharmacy purchases
Source: Merck's second-quarter 2026 earnings call, August 4, 2026.
Written by GetSignal with AI from the company's earnings call.
Not investment advice.
More earnings call briefs
- Merck says 2027 will be a year of investment with moderate revenue growth
MRK Merck Q3 2026 call
- Constellation Energy expects nuclear uprate costs of about $4.3 billion
CEG Constellation Energy Q3 2026 call
- Howard Hughes Holdings says its insurance ambition is a return on equity in excess of 20%
HHH Howard Hughes Holdings Q3 2026 call
- Brookfield Asset Management now sees 2026 earnings modestly below early view
BAM Brookfield Asset Management Q3 2026 call
- Enbridge says it expects 2026 results at the midpoint of its guidance range
ENB Enbridge Q3 2026 call
